BRCA1 and hypoparathyroidism-retardation-dysmorphism syndrome: BRCA1/BRCA2 biallelic alterations lead to BRCA1/BRCA2 loss of function, resulting in homologous recombination deficiency (HRD) which is targetable by PARPi and other DNA‐damaging agents.